Phase I clinical trial of IA013e for Staphylococcus aureus infections
Latest Information Update: 21 Jul 2025
At a glance
- Drugs IA 013 (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions
Most Recent Events
- 21 Jul 2025 New trial record
- 01 Dec 2022 According to IMMUNARTES LLC media release, it has received a funding up to $10.4 Million from National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH),Department of Health and Human Services, under Contract No. 75N93022C00057,which will support d IND-enabling studies of f IA013 Phase I trial.